Zevra Therapeutics (ZVRA) Competitors $9.78 +0.38 (+3.99%) Closing price 07/3/2025 03:52 PM EasternExtended Trading$9.54 -0.24 (-2.45%) As of 07/3/2025 04:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ZVRA vs. APGE, CGON, IDYA, AGIO, BLTE, INDV, IRON, ADPT, HRMY, and SPRYShould you be buying Zevra Therapeutics stock or one of its competitors? The main competitors of Zevra Therapeutics include Apogee Therapeutics (APGE), CG Oncology (CGON), IDEAYA Biosciences (IDYA), Agios Pharmaceuticals (AGIO), Belite Bio (BLTE), Indivior (INDV), Disc Medicine (IRON), Adaptive Biotechnologies (ADPT), Harmony Biosciences (HRMY), and ARS Pharmaceuticals (SPRY). These companies are all part of the "pharmaceutical products" industry. Zevra Therapeutics vs. Its Competitors Apogee Therapeutics CG Oncology IDEAYA Biosciences Agios Pharmaceuticals Belite Bio Indivior Disc Medicine Adaptive Biotechnologies Harmony Biosciences ARS Pharmaceuticals Zevra Therapeutics (NASDAQ:ZVRA) and Apogee Therapeutics (NASDAQ:APGE) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, profitability, analyst recommendations, media sentiment, valuation, earnings, risk and dividends. Do analysts rate ZVRA or APGE? Zevra Therapeutics currently has a consensus price target of $23.14, indicating a potential upside of 136.51%. Apogee Therapeutics has a consensus price target of $95.80, indicating a potential upside of 101.47%. Given Zevra Therapeutics' stronger consensus rating and higher possible upside, equities research analysts plainly believe Zevra Therapeutics is more favorable than Apogee Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Zevra Therapeutics 0 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 3.11Apogee Therapeutics 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has more risk & volatility, ZVRA or APGE? Zevra Therapeutics has a beta of 1.97, meaning that its share price is 97% more volatile than the S&P 500. Comparatively, Apogee Therapeutics has a beta of 1.47, meaning that its share price is 47% more volatile than the S&P 500. Is ZVRA or APGE more profitable? Apogee Therapeutics has a net margin of 0.00% compared to Zevra Therapeutics' net margin of -226.78%. Apogee Therapeutics' return on equity of -28.35% beat Zevra Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Zevra Therapeutics-226.78% -201.05% -53.55% Apogee Therapeutics N/A -28.35%-26.98% Does the media refer more to ZVRA or APGE? In the previous week, Apogee Therapeutics had 1 more articles in the media than Zevra Therapeutics. MarketBeat recorded 8 mentions for Apogee Therapeutics and 7 mentions for Zevra Therapeutics. Zevra Therapeutics' average media sentiment score of 0.68 beat Apogee Therapeutics' score of 0.42 indicating that Zevra Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Zevra Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Apogee Therapeutics 2 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do institutionals and insiders believe in ZVRA or APGE? 35.0% of Zevra Therapeutics shares are held by institutional investors. Comparatively, 79.0% of Apogee Therapeutics shares are held by institutional investors. 2.4% of Zevra Therapeutics shares are held by company insiders. Comparatively, 42.8% of Apogee Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Which has better valuation & earnings, ZVRA or APGE? Zevra Therapeutics has higher revenue and earnings than Apogee Therapeutics. Apogee Therapeutics is trading at a lower price-to-earnings ratio than Zevra Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioZevra Therapeutics$23.61M22.66-$105.51M-$1.90-5.15Apogee TherapeuticsN/AN/A-$182.15M-$3.60-13.21 SummaryZevra Therapeutics beats Apogee Therapeutics on 10 of the 16 factors compared between the two stocks. Get Zevra Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ZVRA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ZVRA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ZVRA vs. The Competition Export to ExcelMetricZevra TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$532.58M$2.43B$5.54B$9.05BDividend YieldN/A1.78%5.24%4.02%P/E Ratio-5.158.9827.4320.22Price / Sales22.66682.84416.87118.64Price / CashN/A158.5936.8958.07Price / Book13.224.588.035.67Net Income-$105.51M$31.34M$3.18B$249.13M7 Day Performance8.72%3.25%2.88%3.28%1 Month Performance10.82%7.08%3.69%5.56%1 Year Performance129.69%0.17%36.02%21.12% Zevra Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ZVRAZevra Therapeutics2.7644 of 5 stars$9.79+4.0%$23.14+136.5%+127.3%$532.58M$23.61M-5.1520News CoverageAnalyst ForecastAnalyst RevisionAPGEApogee Therapeutics2.9043 of 5 stars$43.38-1.0%$94.60+118.1%+26.8%$2.02BN/A0.0091News CoverageAnalyst ForecastInsider TradeHigh Trading VolumeCGONCG Oncology2.3866 of 5 stars$25.95-0.5%$58.67+126.1%-12.8%$1.99B$1.14M-17.1961IDYAIDEAYA Biosciences3.5483 of 5 stars$21.37-4.1%$53.42+150.0%-33.6%$1.95B$7M0.0080High Trading VolumeAGIOAgios Pharmaceuticals4.1241 of 5 stars$33.47-0.5%$58.60+75.1%-14.2%$1.95B$36.50M2.98390Insider TradeBLTEBelite Bio2.475 of 5 stars$59.04-1.4%$96.67+63.7%+30.6%$1.91BN/A0.0010News CoverageAnalyst ForecastGap UpINDVIndivior2.0748 of 5 stars$13.95+1.9%$15.00+7.5%+5.4%$1.89B$1.19B8.011,051News CoverageHigh Trading VolumeIRONDisc Medicine3.057 of 5 stars$54.50+0.7%$96.70+77.4%+23.2%$1.87BN/A0.0030News CoverageAnalyst ForecastHigh Trading VolumeADPTAdaptive Biotechnologies3.346 of 5 stars$11.79-3.0%$10.57-10.3%+253.3%$1.85B$178.96M0.00790News CoverageGap UpHigh Trading VolumeHRMYHarmony Biosciences4.8008 of 5 stars$31.98+0.4%$53.63+67.7%+3.9%$1.83B$714.73M12.16200Positive NewsHigh Trading VolumeSPRYARS Pharmaceuticals3.2596 of 5 stars$18.20+0.7%$31.00+70.3%+81.4%$1.78B$89.15M0.0090Insider TradeHigh Trading Volume Related Companies and Tools Related Companies Apogee Therapeutics Alternatives CG Oncology Alternatives IDEAYA Biosciences Alternatives Agios Pharmaceuticals Alternatives Belite Bio Alternatives Indivior Alternatives Disc Medicine Alternatives Adaptive Biotechnologies Alternatives Harmony Biosciences Alternatives ARS Pharmaceuticals Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ZVRA) was last updated on 7/5/2025 by MarketBeat.com Staff From Our PartnersTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold prices are breaking records. But while everyone else is fixated on headlines… They're missing somet...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Zevra Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Zevra Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ZVRA Stock Alerts